Entera Bio (NASDAQ:ENTX) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 20 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $42.00 thousand in sales this quarter.